氟喹诺酮治疗社区获得性肺炎的优势
被引量:2
Advantage of Treating Community Acquired Pheumonia with Fluoroquinolone
摘要
社区获得性肺炎(CAP)是常见的感染性疾病.美国每年大约有200~300万CAP患者,约50万患者需入院治疗.尽管近年来抗感染药物不断发展,但CAP患者的病死率仍然很高.
出处
《中华医学信息导报》
2005年第7期19-19,共1页
China Medical News
同被引文献9
-
1陈军.左氧氟沙星治疗的几点新见解[J].国外医药(抗生素分册),2005,26(3):121-123. 被引量:19
-
2[1]American Thoracic Society.Guidelines for the initial management of adult with CAP[J].Am.Rev.Resoir Dis,2001,163:1354-1370.
-
3Ramirez JA. Switch therapy in community - acquired pneumonia [ J]. Diagn Microbiol Infect Dis, 1995, 22:219 -223.
-
4Moran GJ. New direction in anti infective therapy for community acquired pneumonia in the emergency department [ J ]. Pharmacogherapy, 2001, 21: 95-99.
-
5Aguas CM, Ports BM, Delas AJ. Protocols implementing in a university hospital, an assessment of various methods [J]. Farm Hosp, 2004, 28 : 334 - 348.
-
6Marrle TJ, Lan CY, heeler SL, et al. A control trial of a critical pathway for treatment of community acquired pneumonia [ J]. JAMA, 2000, 283 : 7492 - 7755.
-
7Sevinc F, Prins JM, Koopmans RP, et al. Early switch from intravenous tooral antibiotics : guidelines and implementation in a large teaching hospital [J]. J Antimicrob Chemother, 1999, 43:601-606.
-
8社区获得性肺炎诊断和治疗指南(草案)[J].中华结核和呼吸杂志,1999,22(4):199-201. 被引量:1036
-
9葛庆华,刘戈,周臻,王浩,傅民.三种头孢克洛胶囊的生物等效性研究[J].中国医药工业杂志,2002,33(7):330-333. 被引量:7
-
1汪复.氟喹诺酮类药物的临床应用现状[J].中华医学信息导报,1999,0(16):2-3.
-
2傅得兴,谢荣瑞.新型诺酮类药物的不良反应及相互作用[J].中国药学杂志,1990,25(2):100-101. 被引量:4
-
3覃开羽,黄新,吴敏,梁宇红.门诊氟喹诺酮类药物不合理用药分析[J].西南国防医药,2009,19(3):318-320. 被引量:9
-
4赵自恒.浅析氟喹诺酮类药物不良反应与临床合理应用[J].中国保健营养(下半月),2010(12):165-166.
-
5谢廷良.氟喹诺酮类药物的罕见不良反应[J].海峡药学,2009,21(1):149-152.
-
6程怀孟.喹诺酮类药物使用三注意[J].保健与生活,2012(7):19-19.
-
7周启才.喹诺酮类药物的合理应用及作用特点[J].中国当代医药,2010,17(11):122-122. 被引量:4
-
8孙淑娜.氟哇诺酮类药物分析[J].健康必读(下),2011(3):306-306.
-
9吕伟青.氟硅诺酮类药物的现状与展望[J].三维药讯,1994(1):11-16.
-
10王成绪,吴宜艳,张久云,张德云.睳诺酮类药物的开发应用[J].牡丹江医学院学报,1996,17(3):31-34.